AR063240A1 - Derivados de n-aril pirazol,composiciones farmaceuticas que los contienen y usos para el tratamiento de la diabetes tipo2,y enfermedades relacionadas. - Google Patents

Derivados de n-aril pirazol,composiciones farmaceuticas que los contienen y usos para el tratamiento de la diabetes tipo2,y enfermedades relacionadas.

Info

Publication number
AR063240A1
AR063240A1 ARP070104489A ARP070104489A AR063240A1 AR 063240 A1 AR063240 A1 AR 063240A1 AR P070104489 A ARP070104489 A AR P070104489A AR P070104489 A ARP070104489 A AR P070104489A AR 063240 A1 AR063240 A1 AR 063240A1
Authority
AR
Argentina
Prior art keywords
alkyl
arylalkyl
aryl
heteroaryl
hydrogen
Prior art date
Application number
ARP070104489A
Other languages
English (en)
Original Assignee
Amgen Inc
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Daiichi Sankyo Co Ltd filed Critical Amgen Inc
Publication of AR063240A1 publication Critical patent/AR063240A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

Reivindicacion 1: Un compuesto caracterizado porque tiene la formula 2 o su sal, solvato o profármaco farmacéuticamente aceptable, en donde L es una union divalente seleccionada de entre el grupo que consiste de un enlace simple, alquileno C1-5, alquenileno C2-5, -(CH2)n-O-(CH2)p-, -(CH2)n-N(R6)-(CH2)p-,-(CH2)n-CH(NR6R7)-(CH2)p-, -(CH2)n-CH(OR6)-(CH2)p-, -(CH2)n-S(O)kN(R7)-(CH2)p-, -(CH2)n-C(O)N(R7)-(CH2)p-, -(CH2)n-C(O)N(R7)C(R8)H-(CH2)p-, -(CH2)n-N(R7)C(O)N(R8)-(CH2)p-, -(CH2)n-C(O)- (CH2)p-, -(CH2)n-C(=NOR6)-(CH2)p-, -(CH2)n-C(O)O-(CH2)p-, -(CH2)n-N(R7)S(O)kN(R8)-(CH2)p- y -(CH2)-N(R7)CO2-(CH2)p-, en donde cada subíndice n y subíndice p es independientemente 0, 1, 2 o 3; V es cicloalquilo C3-7, heterocicloalquilo C3-7, arilo, heteroarilo, arilalquilo C1-4, o heteroarilalquilo C1-4; W es un enlace simple, alquileno C1-5, alquenileno C2-5, -O-, -S(O)k-, -C(O)-, -NR6- o -CH2NR6-; R1 es alquilo C1-6, alquenilo C1-6, heteroalquilo C2-6, cicloalquilo C3-7, heterocicloalquilo C3-7, arilo, heteroarilo, arilalquilo C1-4 o heteroarilalquilo C1-4; R2 es hidrogeno, halogeno alquilo C1-6, -CN, haloalquilo C1-6, alcoxi C1-6, haloalcoxi C1-6 o alquenilo C2-6; opcionalmente, R2 y W toman juntos la forma de un anillo fusionado de 5- o 6- miembros que contienen 0, 1, 2 o 3 heteroátomos seleccionados de O, S, y N; cada R3 y R5 es independientemente seleccionado de entre hidrogeno, hidroxi, halogeno, -CN, alquilo C1-6, haloalquilo C1-6, alquiloxi C1-6, y haloalcoxi C1-6; R4 es alquilo C1-8, heteroalquilo C2-8, cicloalquilo C3-7, arilo, heteroarilo, arilalquilo C1-4 o heteroarilalquilo C1-4; R6 es hidrogeno, alquilo C1-8, fluoroalquilo C1-4, heteroalquilo C2-8, arilo, heteroarilo, arilalquilo C1-4, -C(O)R', -CO2R', - C(O)NR'Rö, -S(O)kR' o -S(O)kNR'Rö; cada R7 y R8 es independientemente seleccionado de entre hidrogeno, alquilo C1-8, fluoroalquilo C1-4, heteroalquilo C2-8, arilo, heteroarilo, y arilalquilo C1-4; cada R' y Rö es independientemente hidrogeno, alquilo C1-6, cicloalquilo C3-8, arilo o arilalquilo C1-4; y cada subíndice k es independientemente 0, 1 o 2.
ARP070104489A 2006-10-10 2007-10-10 Derivados de n-aril pirazol,composiciones farmaceuticas que los contienen y usos para el tratamiento de la diabetes tipo2,y enfermedades relacionadas. AR063240A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85108306P 2006-10-10 2006-10-10

Publications (1)

Publication Number Publication Date
AR063240A1 true AR063240A1 (es) 2009-01-14

Family

ID=39047570

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104489A AR063240A1 (es) 2006-10-10 2007-10-10 Derivados de n-aril pirazol,composiciones farmaceuticas que los contienen y usos para el tratamiento de la diabetes tipo2,y enfermedades relacionadas.

Country Status (12)

Country Link
US (1) US8022061B2 (es)
EP (1) EP2079728B1 (es)
JP (1) JP2010505957A (es)
AR (1) AR063240A1 (es)
AU (1) AU2007308154A1 (es)
CA (1) CA2675511A1 (es)
CL (1) CL2007002904A1 (es)
ES (1) ES2430821T3 (es)
MX (1) MX2009003821A (es)
PE (1) PE20080858A1 (es)
TW (1) TW200831491A (es)
WO (1) WO2008045484A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101547917A (zh) 2006-12-08 2009-09-30 霍夫曼-拉罗奇有限公司 用作jnk调节剂的取代的嘧啶类化合物及它们的应用
ES2551095T3 (es) * 2007-07-19 2015-11-16 Lundbeck, H., A/S Amidas heterocíclicas de 5 miembros y compuestos relacionados
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP5298129B2 (ja) 2007-09-06 2013-09-25 メルク・シャープ・アンド・ドーム・コーポレーション 可溶性グアニレートシクラーゼ活性化因子
JP5411300B2 (ja) 2009-02-26 2014-02-12 メルク・シャープ・アンド・ドーム・コーポレーション 可溶性グアニレートシクラーゼ活性化剤
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011146354A1 (en) * 2010-05-20 2011-11-24 Merck Sharp & Dohme Corp. Novel prolylcarboxypeptidase inhibitors
US9365574B2 (en) 2010-05-27 2016-06-14 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
JP5605104B2 (ja) * 2010-09-10 2014-10-15 セントラル硝子株式会社 ピラゾール化合物の製造方法
AR087701A1 (es) * 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
PT2928474T (pt) 2012-12-07 2019-01-30 Chemocentryx Inc Diazol lactamas
AU2013364038B2 (en) 2012-12-21 2018-04-05 Chemocentryx, Inc. Diazole amides
CN103772282B (zh) * 2014-02-26 2015-09-23 上海毕得医药科技有限公司 一种3-叔丁基-1h-吡唑-4-甲醛的制备方法
WO2016138631A1 (en) 2015-03-03 2016-09-09 Eli Lilly And Company Imidazo benzamide compounds
MY196648A (en) * 2016-02-05 2023-04-27 Denali Therapeutics Inc Inhibitors of Receptor-Interacting Protein Kinase 1
JP2019510832A (ja) 2016-04-07 2019-04-18 ケモセントリクス，インコーポレーテッド Ｐｄ−１阻害剤又はｐｄ−ｌ１阻害剤と組み合わせてｃｃｒ１アンタゴニストを投与することによる腫瘍負荷の低減
PT3552017T (pt) 2016-12-09 2022-05-04 Denali Therapeutics Inc Compostos úteis como inibidores de ripk1
PE20201068A1 (es) * 2018-04-04 2020-10-19 Japan Tobacco Inc Compuestos de pirazol sustituidos con heteroarilo y uso farmaceutico de los mismos
US11179371B2 (en) 2018-07-04 2021-11-23 Boehringer Ingelheim International Gmbh Triazole benzamide derivatives as GPR142 agonists
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3778433A (en) 1969-04-18 1973-12-11 Sumitomo Chemical Co Process for producing benzodiazepine derivatives
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
JPH04145081A (ja) 1990-10-06 1992-05-19 Kumiai Chem Ind Co Ltd ピラゾールカルボン酸誘導体及び除草剤
TW312694B (es) 1994-09-26 1997-08-11 Daiichi Seiyaku Co
US5883105A (en) 1996-04-03 1999-03-16 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AR038955A1 (es) 1996-12-05 2005-02-02 Amgen Inc Compuestos de pirimidinona y piridona sustituidos y metodos para su uso
US6169086B1 (en) 1997-01-27 2001-01-02 Daiichi Pharmaceutical Co., Ltd. Pyrazole derivatives
AU725548B2 (en) 1997-03-11 2000-10-12 E.I. Du Pont De Nemours And Company Heteroaryl azole herbicides
BR0111158A (pt) 2000-05-12 2004-04-06 Genzyme Corp Composto e sais fisiológicos do mesmo, método para tratar uma condição mediana por tnf-a em um paciente
AU2001280099A1 (en) 2000-08-25 2002-04-02 Sankyo Company Limited 4-acylaminopyrazole derivatives
US20040198758A1 (en) 2001-08-17 2004-10-07 Rapado Liliana Parra N-heterocyclyl substituted thienyloxy-pyrimidines used as herbicides
WO2003037274A2 (en) 2001-11-01 2003-05-08 Icagen, Inc. Pyrazole-amides and-sulfonamides
DE10234876A1 (de) 2002-07-25 2004-02-05 Bayer Cropscience Gmbh 4-Trifluormethylpyrazolyl substituierte Pyridine und Pyrimidine
JP3774184B2 (ja) 2002-10-25 2006-05-10 株式会社フジクラ 光ファイバ心線テープ被覆除去具及び光ファイバ心線テープ被覆除去方法
DK1618092T3 (da) 2003-05-01 2011-01-31 Bristol Myers Squibb Co Aryl-substituerede pyrazol-amidforbindelser, der er anvendelige som kinasehæmmere
JP2004339080A (ja) 2003-05-13 2004-12-02 Tokyo Institute Of Technology ピラゾ−ル誘導体を含有する高血圧治療剤
US6818631B1 (en) 2003-08-15 2004-11-16 Nippon Soda Co. Ltd. Fungicidal pyrimidine derivatives
EA010568B1 (ru) 2003-12-15 2008-10-30 Ньюрокрайн Байосайнсиз Инк. 2,6-бисгетероарил-4-аминопиримидины в качестве антагонистов аденозиновых рецепторов
EP1751139B1 (en) 2004-04-30 2011-07-27 Bayer HealthCare LLC Substituted pyrazolyl urea derivatives useful in the treatment of cancer
WO2007008541A2 (en) * 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
US20090275586A1 (en) * 2006-10-06 2009-11-05 Kalypsys, Inc. Heterocyclic inhibitors of pde4

Also Published As

Publication number Publication date
CL2007002904A1 (es) 2008-06-06
TW200831491A (en) 2008-08-01
ES2430821T3 (es) 2013-11-21
EP2079728A1 (en) 2009-07-22
AU2007308154A1 (en) 2008-04-17
MX2009003821A (es) 2009-05-25
JP2010505957A (ja) 2010-02-25
EP2079728B1 (en) 2013-09-25
PE20080858A1 (es) 2008-08-06
WO2008045484A1 (en) 2008-04-17
US8022061B2 (en) 2011-09-20
CA2675511A1 (en) 2008-04-17
US20080153778A1 (en) 2008-06-26

Similar Documents

Publication Publication Date Title
AR063240A1 (es) Derivados de n-aril pirazol,composiciones farmaceuticas que los contienen y usos para el tratamiento de la diabetes tipo2,y enfermedades relacionadas.
AR062510A1 (es) Derivados de piridona con actividad antagonista de mch y medicamentos que comprenden estos compuestos
AR077505A1 (es) Compuestos de piridina y sus usos
AR051294A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
PE20081475A1 (es) Arilamidas sustituidas por tiazol u oxazol
AR048315A1 (es) Compuestos heterociclicos inhibidores de la produccion de citocinas; composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades inflamatorias y oncologicas.
AR054083A1 (es) Compuestos imidazol y su utilizacion paar preparar medicamentos
AR062503A1 (es) Derivados de pirido[2, 3-d]pirimidina y pirazin[2, 3-d]pirimidina, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de mtor.
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
AR084768A1 (es) Moduladores de la senda de complemento y usos de los mismos
AR082633A1 (es) Analogos de tetraciclina
AR051092A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa
AR051094A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
AR059571A1 (es) Derivados de octahidro-pirrolo[3,4-c]pirrol, composiciones farmaceuticas
AR051091A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
AR066669A1 (es) Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas.
AR054799A1 (es) Derivados de oxindol
AR078045A1 (es) Derivados de pirimidina, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer
AR051095A1 (es) Derivados heterociclicos y su uso comoinhibidores de la estearoil-coa desaturasa
PE20090042A1 (es) Analogos de ciclopamina
CO5580788A2 (es) Compuestos de bencimidazol sustituidos utiles como inhibidores de proteina cinasas
AR049711A1 (es) Compuestos heterociclicos condensados como inhibidores de la aldosterona sintasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el hiperaldosterismo y por una liberacion excesiva de cortiso
AR066020A1 (es) Derivados de imidazolidin-2, 4-diona, una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de parp-1.
PE20081662A1 (es) DERIVADOS DE 6-OXO-6,7-DIHIDRO-5H-DIBENZO[b,d]AZEPIN-7-ILO
UY29312A1 (es) Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones

Legal Events

Date Code Title Description
FB Suspension of granting procedure